^
Association details:
| Biomarker: | STK11 mutation |
|---|---|
| Cancer: | Lung Non-Small Cell Squamous Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
The influence of STK11 mutation on acquired resistance to immunotherapy in advanced non-small cell lung cancer with Lynch syndrome: a case report and literature review
Published date:
03/23/2021
Excerpt:
a patient who was diagnosed with advanced lung squamous cell carcinoma...patient subsequently received pembrolizumab (200 mg, ivgtt, q3w) as first line therapy and achieved stable disease (SD) as the best response. After eight treatment cycles, the patient suffered disease progression (PD), and an STK11 frameshift mutation was newly identified...STK11 could contribute to pembrolizumab acquired resistance...
DOI:
10.21037/apm-20-1639
